Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS extension study of iscalimab in Sjögren syndrome
MOH_2021-05-19_009971Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of iscalimab in Sjögren's syndrome (2 arms), sponsored by Novartis. Started Mar 2021; status: recruiting.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2021-05-19_009971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-19_009971.